loader

Argenica Therapeutics

ASX:AGN

Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates.

Featured Articles and Interviews
Press Releases

Preclinical Data Shows ARG-007 Inhibits One Of The Main Causes Of Alzheimer’s Disease

Argenica Therapeutics Ltd is engaged in the development and commercialization of novel drug candidates. Its lead neuroprotective peptide candidate, ARG007 improves outcomes in pre-clinical stroke models and is in the process of being verified for its safety and toxicology before commencing Phase 1 clinical trials in humans.

Interactive Chart

×